SMAD3 and Alzheimer disease: In addition to the high confidence, experimentally validated pericytic SMAD3-astrocytic VEGFA interactions and perturbations in AD with consequences in BBB disintegrity, our study also provides detailed information on human brain vascular and astrocytic transcriptional perturbations and other predicted molecular pairs which can be followed up in future studies.